Abdelaziz, L. A., Taha, H. F., Ali, M. M., Abdelgawad, M. I., & Elwan, A. (2021). Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: A prospective randomized multi-centric Egyptian study. Termedia Publishing House.
Style de citation Chicago (17e éd.)Abdelaziz, Lobna A., Heba F. Taha, Magid M. Ali, Marwa I. Abdelgawad, et Amira Elwan. Tolerability and Outcome of Sunitinib by Giving 4/2 Schedule Versus 2/1 schedule in Metastatic Renal Cell Carcinoma Patients: A Prospective Randomized Multi-centric Egyptian Study. Termedia Publishing House, 2021.
Style de citation MLA (8e éd.)Abdelaziz, Lobna A., et al. Tolerability and Outcome of Sunitinib by Giving 4/2 Schedule Versus 2/1 schedule in Metastatic Renal Cell Carcinoma Patients: A Prospective Randomized Multi-centric Egyptian Study. Termedia Publishing House, 2021.